Outside the Macclesfield of Astrazneca factory.
Christopher Forllong Getty Images News | Gety pictures
Astrazeneca He said on Friday that she will invest $ 2.5 billion at the Chinese Research and Development Center in Beijing, where the British giant of medicines is seeking to recover from Chinese investigations into import taxes.
The new axis is expected to reach the workforce in Beijing from Astrazneca to about 1700 employees.
Astrazzinica said that investing in Beijing comes as part of a partnership with the municipal government in the city and the administrative office of the field of economic development of economic technology in Beijing.
Under the deal, Astrazneca will enter cooperation in the field of research and development with Harbour Biomed and Syneron BIO and will launch a joint project with Biokangtai to develop and produce market vaccines for respiratory diseases and other infectious diseases.
The partnership with Biokangtai will witness that the company opens the first vaccine manufacturing facility in China.
The Beijing Research Center in Astrazneca will be the second of its kind in China, as the company has already has a research and development center in Shanghai. “The Beijing Center” will participate with advanced biology and artificial intelligence in Beijing and be an important part of our global efforts to bring innovative drugs to patients all over the world. “
Astrazneca shares fell by about 1 % at 11:13 am in London.
Chinese investigation
Last month, Astrazneca said it may face a fine of Chinese authorities of $ 4.5 million, in relation to 900,000 dollars of unpaid import duties.
The company said that the investigations into these allegations were underway in China in Full year profit report In February.
The company said at the time: “To the best in knowing Astrazneca, the imported taxes referred to in the evaluation opinion are linked to (IMFINZI and IMudo and IMudo.” “A fine of one and five times, the amount of unpaid import taxes can also be imposed if Astrazeneca is found responsibility. Astrazneca continues to fully cooperate with Chinese authorities.
Soreriot said in his statement on Friday that the $ 2.5 billion investment in Beijing showed “the commitment of China’s continuation” to Estrazineica.
This urgent news story is updated.
https://image.cnbcfm.com/api/v1/image/106993138-1640251979467-gettyimages-57611036-57608200CF001_Drugs_Giant_A.jpeg?v=1742555256&w=1920&h=1080
Source link